PFIZER ENABLE BONE MINERAL DENSITY STUDIES REQUIRED TO SUPPORT APPROVAL FOR ARTHRITIS, FDA COMMITTEE DECIDES; SAFETY QUESTIONS OUTWEIGH EFFICACY BENEFIT
Executive Summary
The long-term effects of Pfizer's Enable (tenidap) on bone mineral density need to be studied to support approval of the drug for osteoarthritis and rheumatoid arthritis, FDA's Arthritis Advisory Committee recommended May 7.